Trial evaluates safety and efficacy of belumosudil in children with refractory chronic graft-versus-host disease, suggesting alternate treatment options.
Key Points
Overall response rate assessed by Week 24 in participants aged 1 to <18 years with moderate-to-severe cGvHD.
Multicenter open-label study investigating belumosudil administering a daily oral formulation for systemic therapy.
Key inclusion requires prior hematopoietic stem cell transplantation and moderate-to-severe cGvHD as defined by NIH criteria.
Study aims for safety evaluation and long-term follow-up to improve treatment outcomes for pediatric patients.